Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dementia Consortium

- PMLiVE

NICE turns down Keytruda/Inlyta combo for kidney cancer

Cost-effectiveness agency says the long-term benefit is uncertain

- PMLiVE

Double blow to amyloid drug hopes as Roche, Lilly trial fails

The two investigational candidates were unable to show benefit

- PMLiVE

Merck spins off low-growth drugs in a ‘purposeful shift’ of focus

Fourth quarter results overshadowed by spin off announcement

- PMLiVE

Lilly launches migraine med Reyvow at $640 per eight-pill pack

Enters increasingly competitive market

- PMLiVE

Lilly posts higher-than-expected profit as new drugs lift outlook

Sales boosted by growth of Trulicity and Taltz

- PMLiVE

Lilly will aim for one $1bn-$5bn deal per quarter in 2020

Company seeks to bolster pipeline with a string of M&A activity

- PMLiVE

Lilly ends $1.4bn deal with immuno-oncology biotech NextCure

Lilly paid $25m upfront on top of a $15m equity investment

- PMLiVE

Lilly extends range of cut-price insulins in the US

Announces discounts in response to increasing pricing criticism

Bayer symbol

Bayer bulks up in women’s health again with non-hormonal contraceptive deal

If approved candidate would become a first-in-category therapy

- PMLiVE

Lilly expands dermatology portfolio with $1.1bn Dermira deal

Deal includes FDA fast-tracked eczema drug

Bayer symbol

Bayer extends alliance with Evotec in women’s health

Five-year research agreement focuses on polycystic ovary syndrome

- PMLiVE

Merck strengthens KRAS stake with Taiho and Astex partnership

Partner companies could gain $2.5bn in milestone payments

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links